Antineo: Acute Promyelocytic Leukemia tumour model – HL-60
-
HL-60 cells
Human HL-60 cells were isolated from the peripheral blood of a patient with Acute Promyelocytic
Leukemia.
-
Tumour growth in vivo
Tumour fragment were surgically implanted in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing Hl-60 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the HL-60 cells as xenograft
Mean ± SEM (n=6; take rate 100%)
Antineo can also perform an IV implantation, using hCD45 Flow Cytometry as follow-up of tumour progression.
-
Standard-Of-Care Drug Reponses
Daunorubicine 4 mg/kg / Aracytine 10 mg/kg, once per week → Response
Figure 2: (View PDF)
Effect of Dauno/AraC treatment on HL-60 tumour growth
Mean ± SEM (n=6 per group; take rate 100%)